Current and Future Immunotherapy Approaches for HCC: Evidence, Guidance, and Resources

Interact with experts during a 1-hour, CME/CE-certified live meeting examining recent advances and current best practices in the use of immune checkpoint inhibitors for treating hepatocellular carcinoma. This program will specifically focus on educating hepatologists, medical oncologists, and other members of the multidisciplinary care team. Register today!


  • Overview of HCC treatment
  • How immune checkpoint inhibitors fit into the treatment landscape for advanced HCC
    • Key data in the first-line and second-line settings
  • Practical guidance
    • Key patient considerations for treatment with immune checkpoint inhibitors (including cirrhosis, HBV/HCV status)
    • Managing key immune-related adverse events
    • Best practices in multidisciplinary care
  • Final thoughts and audience question and answer session


Date / Time
Event Details


Program Director
Lipika Goyal, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Program Director
Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners in their clinical use of optimal HCC immunotherapy options.

Target Audience
This program is intended for hepatologists and other healthcare providers who care for patients with HCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients with HCC most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, comorbid liver diseases, and patient characteristics and preferences
  • Review recent therapeutic advances and FDA approvals for the use of immune checkpoint inhibitor–based treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Evaluate clinical data on the use of novel systemic for patients with relapsed/refractory advanced HCC and integrate this information into clinical practice, taking into consideration the available clinical evidence, preexisting cirrhosis and other liver diseases, known agent toxicity/ tolerability profiles, expert recommendations, and patient preferences
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC, while also managing comorbid liver diseases
  • Plan strategies and care plans for coordination of treatment of HCC to maximize benefit for local and systemic therapies.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-073-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.